Brazikumab, a molécula recente, está atraindo grande interesse na área médica devido ao seu potencial para tratar doenças inflamatórias crônicas. Este anticorpo específico age inibindo a citocina IL-17A, uma chave responsável de muitos processos inflamatórios . Estudos iniciais sugerem melhorias

Avizakimab, formerly known as BOS161721, represents a novel therapeutic approach to treating immune-mediated disorders. This monoclonal substance selectively targets IL18, a vital signaling molecule implicated in the development of several severe illnesses. Preclinical studies have shown Avizakim

{Atacicept | VT-001: A Novel Approach Atacicept, also known as VT-001 , represents a significant breakthrough in treatment science. This pioneering substance functions as a decoy receptor , effectively neutralizing the activity of TNFSF-13 , a key component in B-cell longevity and im